Medulloblastoma is not one disease. Since a landmark 2012 consensus conference, researchers have recognized four molecular subtypes that differ in who they affect, how they behave, and how well they respond to treatment: WNT, SHH (Sonic Hedgehog), Group 3, and Group 4.1Europe PMC. Molecular subgroups of medulloblastoma: the current consensus These distinctions matter because a child with a WNT tumor and a child with a Group 3 tumor can face radically different odds, even though their brain scans look similar. Understanding the subtypes has begun reshaping how clinicians plan surgery, radiation, and chemotherapy, and it is opening the door to therapies that would have been unthinkable when medulloblastoma was treated as a single entity.
WNT Subtype
WNT-subtype medulloblastomas account for roughly 10 to 15 percent of cases and carry the best prognosis of the four groups, with survival rates above 90 percent.2PubMed Central. WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go? They are driven by activating mutations in a gene called CTNNB1 that switches on the WNT signaling pathway, and they have a surprising anatomical twist: rather than arising in the cerebellum itself, these tumors trace their origins to cells in the dorsal brainstem, specifically a structure called the lower rhombic lip.3Nature. Subtypes of medulloblastoma have distinct developmental origins WNT tumors are most common in older children and adolescents and rarely metastasize at diagnosis.
Because outcomes are already so good, the pressing clinical question is whether treatment can be dialed back to spare children from the harsh side effects of full-dose craniospinal radiation. The answer, so far, is a cautious “not yet.” Two prospective clinical trials tested de-intensification strategies in low-risk WNT patients. One tried omitting upfront craniospinal irradiation; the other tested a chemotherapy-first approach after surgery. Both had to be stopped early because relapse rates climbed to unacceptable levels.2PubMed Central. WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go? The lesson is sobering: even in the “good” subtype, craniospinal radiation still appears essential. Ongoing trials are exploring whether reduced doses can split the difference between curing the tumor and limiting long-term harm.
SHH (Sonic Hedgehog) Subtype
The SHH subtype makes up about 25 to 30 percent of medulloblastomas and has a distinctive age distribution. It peaks in two populations that seem to have little in common: infants under three years old and adults over 16. Those two age groups often carry different driver mutations and different prognoses, which is why researchers increasingly view SHH as an umbrella covering several biologically distinct diseases rather than one uniform group.
What ties them together is aberrant activation of the Sonic Hedgehog signaling pathway, a developmental circuit that normally guides brain-cell proliferation during fetal and early childhood growth. Because the pathway has a known drug target, a compound called vismodegib (a Smoothened antagonist already approved for basal cell carcinoma) entered clinical trials for SHH medulloblastoma. Early results were mixed. In preclinical models, vismodegib initially shrank tumors, but the cancer cells adapted: within about two weeks of continuous treatment, markers of proliferation stopped declining and began rising again, and prolonged treatment did not significantly improve survival in mouse models.4Nature Communications. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy Lab work suggests that combining vismodegib with drugs that activate a metabolic enzyme called AMPK can overcome this resistance and suppress tumor growth more effectively than either approach alone.5PubMed Central. Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib-resistance That combination has not yet been tested in large-scale human trials, but it points toward a strategy of pairing targeted therapy with resistance-busting agents.
One mutation dramatically changes the outlook for SHH patients. When an SHH tumor also carries a TP53 mutation, outcomes are extremely poor, forming what clinicians call an “extremely high-risk group.”6PubMed Central. p53 and Medulloblastoma These SHH/TP53-mutant tumors cluster almost exclusively in children between the ages of five and eighteen, a pattern strikingly different from the broader SHH age distribution.7PubMed Central. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma Identifying TP53 status at diagnosis has become a key part of risk stratification for SHH patients, because it can shift a child from a standard-risk treatment plan into an intensified one.
Group 3
Group 3 is the most aggressive of the four subtypes. It accounts for roughly 20 to 25 percent of medulloblastomas, occurs predominantly in infants and young children, and is overrepresented in males. A defining molecular feature is amplification of the MYC oncogene, which drives unchecked cell growth. In many Group 3 tumors, the amplified MYC gene sits on unusual genetic structures called extrachromosomal DNA or homogeneously staining regions, and a specific enhancer element within those structures has been identified as the switch that activates MYC transcription specifically in these tumors.8PubMed Central. A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates MYC Transcription in Group 3 Medulloblastoma
Group 3 tumors tend to be more aggressive than other subtypes, especially when they have already spread at the time of diagnosis. Survival rates are considerably lower than in WNT tumors, and the risk of recurrence is highest when metastases are present.9Mayo Clinic. Medulloblastoma There is no targeted therapy equivalent to vismodegib for Group 3 yet. Treatment relies on aggressive combinations of surgery, high-dose craniospinal radiation, and intensive chemotherapy. The identification of the MYC-driving enhancer is promising because it suggests a potential drug target, but translating that discovery into a therapy patients can receive is still years away.
Group 4
Group 4 is the most common subtype, making up about 35 to 40 percent of medulloblastomas, and paradoxically the least understood. It affects mostly children and adolescents and, like Group 3, is more frequent in males. For years it was defined largely by what it was not: not WNT, not SHH, and not MYC-amplified. Recent genomic work has begun to fill in the picture. Somatic mutations in Group 4 tumors converge on a protein complex called CBFA, with alterations affecting genes such as CBFA2T2, CBFA2T3, and PRDM6. These tumors transcriptionally resemble early progenitor cells from the cerebellar rhombic lip subventricular zone, essentially brain cells that appear stalled at an immature developmental stage.10Nature. Molecular subgrouping of medulloblastoma
Prognosis for Group 4 is intermediate overall, better than Group 3 but not as favorable as WNT. However, outcomes vary widely within the group depending on specific chromosomal gains and losses, which is one reason researchers have pushed to break Group 4 into finer subtypes (discussed below).
The Blurry Border Between Group 3 and Group 4
One of the more surprising findings in recent years is that Groups 3 and 4 may not be as distinct as the consensus framework implies. RNA-sequencing studies across large patient cohorts show that these two groups exist on a continuous spectrum rather than as two discrete entities. A tumor’s position along that spectrum predicts its likelihood of carrying certain chromosomal changes and its clinical behavior, meaning that some Group 3 tumors resemble Group 4, and vice versa.11Cell Reports / PubMed Central. Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development Developmental biology reinforces this overlap: molecular signatures from a human rhombic-lip-derived lineage align with expression profiles maintained in both Group 3 and Group 4 tumors, suggesting shared cellular origins.12PubMed Central. Unified rhombic lip origins of group 3 and group 4 medulloblastoma
This does not mean the distinction is useless. At the extremes, archetypal Group 3 (high MYC, metastatic, dismal survival) and archetypal Group 4 (CBFA-driven, intermediate survival) look quite different. But many tumors fall somewhere in between, and labeling them as strictly one or the other can obscure clinically relevant biology. The continuum model is gradually influencing how researchers design clinical trials, pushing them toward finer molecular stratification rather than binary group assignments.
Beyond Four Groups
The four-subtype framework was always a starting point, not a final destination. In 2017, an integrative analysis of DNA methylation, gene expression, and copy-number data across 763 medulloblastomas identified 12 distinct subtypes: two within WNT, four within SHH, three within Group 3, and three within Group 4.13PubMed. Intertumoral Heterogeneity within Medulloblastoma Subgroups A later meta-analysis of over 1,500 tumors focused specifically on Group 3 and Group 4 and settled on eight robust subtypes (designated types I through VIII) within those two groups alone, each carrying distinct driver-gene alterations, chromosomal changes, and survival outcomes.14PubMed Central. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
For families and clinicians, the practical consequence is that two children both labeled “Group 4” can face very different risks. The 12-subtype (or 8-subtype, depending on the scheme) approach captures that heterogeneity more accurately and is beginning to inform trial design. It also reveals that the two SHH infant subtypes, for instance, have disparate outcomes and biology despite occupying the same broad group.13PubMed. Intertumoral Heterogeneity within Medulloblastoma Subgroups The challenge is that the more granular the classification, the smaller each patient group becomes, which makes it harder to run statistically powerful clinical trials. Balancing precision with feasibility is one of the field’s central tensions.
How Subtypes Are Identified in Practice
The gold standard for molecular subgrouping is DNA methylation profiling, typically using an Illumina methylation array. This approach is considered the most accurate and robust method for classifying medulloblastomas, particularly for confirming WNT status, and is increasingly recommended for patient stratification in clinical trials.15Neuro-Oncology. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas It also scales well to the 12-subtype and 8-subtype classification schemes.
Not every hospital has access to methylation arrays, though. Simpler, cheaper methods exist. Immunohistochemistry (IHC) can distinguish WNT and SHH tumors reasonably well by staining for specific proteins, but it struggles badly with Groups 3 and 4. In one comparison of 71 pediatric cases, IHC misidentified 23 of 38 Group 3 and Group 4 tumors when measured against a NanoString gene-expression assay as the reference.16PubMed Central. Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods The NanoString nCounter assay, which measures the expression of a panel of signature genes, offers an intermediate option: more accurate than IHC for Group 3 and Group 4, and less resource-intensive than a full methylation array.17PubMed. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres
This hierarchy of diagnostic tools has real consequences for patients. A child treated at a center that relies solely on IHC may be misclassified, which can mean receiving a treatment plan calibrated to the wrong risk group. The push toward molecular subgrouping as a routine part of diagnosis is strong in high-income countries but far from universal.
When Subtype Predictions Don’t Match Outcomes
A study from a resource-limited setting illustrates how context can scramble even well-established subtype prognoses. In a cohort of 88 molecularly subgrouped medulloblastomas, the distribution looked broadly familiar: about 19 percent WNT, 25 percent SHH, 24 percent Group 3, and 32 percent Group 4. But the survival numbers told an unexpected story. Group 3 tumors had dismal progression-free survival of roughly 45 percent, consistent with their reputation. Yet WNT tumors, normally the best performers, showed progression-free survival of only about 70 percent, far below the greater-than-90-percent rates seen in high-income clinical trials. SHH and Group 4 patients did well, at over 83 and 87 percent, respectively.18PubMed Central. Molecular Subgroup Is the Strongest Predictor of Medulloblastoma Outcome in a Resource-Limited Country
These disparities likely reflect differences in the quality and timeliness of care, access to craniospinal radiation, and supportive services rather than biology. The finding underscores that molecular subtype is the strongest predictor of outcome even in low-resource settings, but the absolute survival numbers it predicts depend heavily on the treatment infrastructure available. For families navigating a diagnosis, knowing the subtype is necessary but not sufficient; the treatment environment matters enormously.
What the Immune Landscape Looks Like Across Subtypes
The tumor microenvironment, the mix of immune cells, blood vessels, and support cells surrounding the cancer, is different in each subtype. Single-cell sequencing studies have mapped these differences in detail. WNT tumors show sparse immune-cell infiltration but are enriched in supportive stromal cells like pericytes and astrocytes, and they display elevated blood-vessel formation. Despite the low immune presence, microglia-derived immune cells within WNT tumors tend to be polarized toward an anti-tumor state.19PubMed. Single-cell deconstruction of medulloblastoma microenvironment elucidates subtype-specific immune architectures and prognostic molecular signatures
SHH, Group 3, and Group 4 tumors are more immunosuppressive. They tend to be dominated by tumor-associated macrophages and T cells that are functionally exhausted or regulatory, meaning the immune system is physically present but kept on a leash by the tumor.19PubMed. Single-cell deconstruction of medulloblastoma microenvironment elucidates subtype-specific immune architectures and prognostic molecular signatures An independent study confirmed this general pattern while noting some nuances: SHH tumors showed strong signatures of fibroblasts, T cells, and macrophages, while Group 4 tumors were relatively enriched in cytotoxic lymphocytes compared to other non-WNT groups.20PubMed Central. Subgroup-specific immune and stromal microenvironment in medulloblastoma Overall, though, medulloblastoma as a whole is considered immunologically “cold,” meaning it does not provoke a strong natural immune response. This is a headwind for immunotherapy strategies like checkpoint inhibitors, which work best in tumors the immune system is already trying to fight.
Long-Term Costs of Treatment
Survival statistics tell only half the story. The standard treatment for medulloblastoma, particularly craniospinal radiation, exacts a steep toll on the developing brain and body. Radiation therapy is associated with progressive cognitive decline in children, manifesting as lower IQ scores that continue to drop over at least a decade after treatment.21PubMed. Cognitive consequences of the treatment of medulloblastoma among children The younger a child is at the time of radiation, the greater the damage tends to be.
Endocrine problems are equally common. Hypothyroidism and growth-hormone deficiency are the most frequent radiation-induced hormonal complications. Between 50 and 80 percent of children treated with craniospinal radiation for brain tumors will experience growth failure, driven by a combination of growth-hormone deficiency, spinal shortening from direct radiation effects on bone, precocious puberty, and poor nutrition.22PubMed. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors These effects are not hypothetical future risks; they are the expected trajectory for most survivors who received radiation at a young age.
This is one of the main reasons the subtype classification matters beyond predicting survival. If clinicians can confidently identify low-risk patients, such as WNT-subtype children without metastases, the hope is to eventually reduce radiation doses or replace some radiation with targeted therapy, sparing cognitive and endocrine function. The failed de-intensification trials for WNT tumors show that this is harder than anticipated, but the goal remains central to how the field is thinking about trial design.
Hereditary Risk and Genetic Predisposition
Most medulloblastomas arise from spontaneous mutations, not inherited ones. But a meaningful minority of patients carry germline genetic predispositions that increased their risk from birth. A retrospective and prospective cohort study found that the prevalence of genetic predisposition varies by subtype, with the SHH subgroup carrying the highest rate: about 20 percent of SHH patients in the retrospective cohort had an identifiable germline predisposition.23The Lancet Oncology. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective and prospective cohort study These predispositions include mutations in genes like TP53 (Li-Fraumeni syndrome), PTCH1 (Gorlin syndrome), and SUFU. The practical implication is that genetic counseling and, in some cases, germline testing for newly diagnosed medulloblastoma patients, especially those in the SHH group, can identify families who may benefit from cancer surveillance programs.
How Medulloblastoma Spreads
Medulloblastoma’s most dangerous behavior is leptomeningeal metastasis, the spread of cancer cells through the cerebrospinal fluid to coat the surfaces of the brain and spinal cord. For decades, this was assumed to happen purely by local shedding of cells into the fluid-filled spaces. Whole-genome sequencing of matched primary tumors and metastases revealed a more complex picture. Some somatic mutations were clonal in the metastasis but only present in a small fraction of cells in the primary tumor, suggesting the metastasis grew from a pre-existing subclone that was selected for spread. Intriguingly, very low levels of tumor-derived DNA were also detected in peripheral blood, consistent with the possibility of circulating tumor cells or circulating tumor DNA.24Cell. A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases This raises the prospect that at least some metastases travel through the bloodstream rather than directly through cerebrospinal fluid, a route that, if confirmed, could open new avenues for monitoring and possibly intercepting spread.
Emerging Therapeutic Directions
For SHH tumors specifically, preclinical work is exploring targets beyond the Smoothened receptor. One approach targets a transcription factor called OLIG2 using a small-molecule inhibitor. Researchers have tested this compound in patient-derived organoids, genetically engineered mouse models of SHH medulloblastoma, and patient-derived xenograft tumors as a way to reduce recurrence.25bioRxiv. Targeting OLIG2 increases therapeutic responses in SHH medulloblastoma mouse models and patient-derived medulloblastoma organoids This remains preclinical, meaning no patients have been treated with it yet, but it reflects a broader trend of looking for drug targets that are specific to a given subtype’s biology rather than using the same chemotherapy regimen for everyone.
Immunotherapy is another frontier. CAR T-cell therapy, which has transformed treatment for certain blood cancers, is being explored for medulloblastoma. Reviews of the field describe it as a promising approach, though the immunologically cold microenvironment of most medulloblastoma subtypes poses a significant barrier.26PubMed. Literature review: CAR T-cell therapy as a promising immunotherapeutic approach for medulloblastoma Making engineered immune cells work inside a brain tumor that actively suppresses immune activity is a different challenge than deploying them against leukemia cells circulating freely in the blood. Early-phase trials are underway, but definitive results are still years out.
The broader trajectory of medulloblastoma treatment is a slow migration from “one disease, one protocol” toward subtype-aware, and eventually subtype-specific, therapy. Group 3 patients, who face the worst outcomes, currently lack any targeted agent and rely on brute-force chemotherapy and radiation. Understanding the enhancer mechanism that drives MYC in these tumors is one of the first steps toward changing that.8PubMed Central. A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates MYC Transcription in Group 3 Medulloblastoma Group 4, as the most common and historically most mysterious subtype, is only now yielding the kind of molecular detail that could suggest drug targets. The convergence of mutations on the CBFA complex is a lead, but an early one.10Nature. Molecular subgrouping of medulloblastoma For WNT patients, the question is less about finding new drugs than about figuring out how to safely give less of the treatments that already work, without the relapses that ended the last round of de-escalation trials.